Study wrapper · #726
Mitochondria-derived peptide MOTS-c alleviates hyperoxia-induced bronchopulmonary dysplasia in neonatal mice by activating Nrf2 pathway.
Editor's note
In a neonatal-mouse model of hyperoxia-induced bronchopulmonary dysplasia and in cultured endothelial cells, researchers found that MOTS-c reduced lung structural damage, inflammation, and oxidative stress, and that the animals' own MOTS-c was depleted by hyperoxia. The benefit was Nrf2-dependent: an Nrf2 inhibitor or Nrf2-deficient mice abolished it, a reasonably rigorous causal check. Still, this is a single-model preclinical study. These are preclinical findings; human data are needed before any clinical conclusions can be drawn, and the abstract's framing of MOTS-c as a "potential therapeutic agent" is a hypothesis, not a demonstrated treatment. It reinforces the consistent theme of MOTS-c acting through Nrf2-linked antioxidant defences in animal injury models.
Plain-language abstract
Premature babies on high-oxygen support can develop bronchopulmonary dysplasia, a serious lung condition driven by oxidative stress. Researchers tested MOTS-c, a mitochondria-made peptide, in newborn mice exposed to high oxygen and in human blood-vessel cells. High oxygen lowered the animals' natural MOTS-c and caused stunted growth plus abnormal lung and blood-vessel development. Giving extra MOTS-c reduced these problems, kept cells alive, and helped blood vessels form, while calming inflammation and oxidative stress. Importantly, the researchers showed the benefit depended on a protective protein called Nrf2: when they blocked Nrf2 or used mice lacking it, MOTS-c stopped working, which strengthens the case that Nrf2 is how MOTS-c acts. All of this was in animals and cells, so it cannot show how MOTS-c would affect premature infants; human studies would be needed. It adds to evidence that MOTS-c fights oxidative lung injury through antioxidant pathways.